Search for content, post, videos

Pharmalundensis acquires patent

Pharmalundensis has acquired a patent application to use metabotropic glutamate receptors in group 1 for prevention of intra abdominal adhesions encountered after surgery.

The project was started by Redeco Chem, a company based in Lund, south of Sweden and its collaboration partners. Pharmalundensis will during the fall of 2013 carry out further studies to evaluate the effects. Should the company thereafter chose to commercialize the project, Pharmalundensis will provide Redeco Chem with a purchase price of 100 000 SEK and an additional 10 percent from Pharmalundensis’ future net revenues from the project.

The company will also pay the filing of national patent applications in the US and in Europe. Should the treatment prove to be effective, Pharmalundensis has hopes for more revenues from licensing agreements from companies with similar substances.

Abdominal adhesions (or intra-abdominal adhesions) are most commonly caused by abdominal surgical procedures. The adhesions start to form within hours after surgery and may cause internal organs to attach to the surgical site or to other organs in the abdominal cavity. Adhesion-related twisting and pulling of internal organs can result in complications such as abdominal pain or intestinal obstruction.